Emcure Pharmaceuticals announced the appointment of Mr. C S Muralidharan as Additional Director (Non-Executive and Independent) following its board meeting held on March 09, 2026. The board meeting commenced at 12:15 p.m. (IST) and concluded at 12:40 p.m. (IST), addressing significant governance matters in compliance with SEBI regulations.

Board Approves Independent Director Appointment

Based on the recommendation of the Nomination and Remuneration Committee, the board approved the appointment of Mr. C S Muralidharan (DIN: 00014740) as an Additional Director (Non-Executive and Independent) with effect from April 01, 2026. He will serve as an Independent Director for an initial term of three consecutive years, subject to approval by the company's members.

Director Profile and Experience

Mr. C S Muralidharan brings extensive corporate experience spanning 40 years across hydrocarbon and pharmaceutical sectors. He has held various board and senior leadership positions across multiple entities in India, Asia, and Europe. His expertise includes strategic partnerships, M&A transactions, enterprise risk management, capital restructuring, enterprise transformation, and ESG initiatives.

His professional background includes roles with prominent organizations including Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, Matrix Laboratories Limited, Watson Group, and Sun Pharmaceutical Industries Limited, where he served as Group Chief Financial Officer. In his last role, he was responsible for global finance, strategy, M&A, investor relations, governance, and compliance.

Qualifications and Educational Background

Mr. Muralidharan holds qualifications as a Cost & Management Accountant with a Master's degree in Commerce. He has completed the Executive Program in General Management from Booth School of Business, University of Chicago, further strengthening his leadership credentials.

Regulatory Compliance and Independence

The company confirmed that Mr. Muralidharan is not debarred from holding directorship by any SEBI order and complies with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018. The appointment was made pursuant to Regulation 30 of the SEBI Listing Regulations and reference HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The appointment ensures independence in his role as he is not related to any existing Directors or Key Managerial Personnel of the company, maintaining corporate governance standards.

Emcure Pharmaceuticals has completed the allotment of 17,000 equity shares to eligible employees under its Employee Stock Option Scheme 2013 (Emcure ESOS 2013). The allotment was approved through a Resolution by Circulation by the company's Nomination and Remuneration Committee on March 03, 2026.

ESOP Allotment Details

The allotment follows the exercise of 17,000 vested stock options by eligible employees under the Emcure ESOS 2013 scheme. Each equity share carries a face value of Rs. 10 and the newly issued shares will enjoy equal rights with existing equity shares of the company.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up share capital. The capital structure has been revised following the incorporation of the newly allotted shares.

Regulatory Compliance

The allotment was conducted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both the National Stock Exchange of India Limited and BSE Limited about this corporate action as required under the regulatory framework.

The newly allotted equity shares will rank pari passu in all aspects with the existing equity shares of Emcure Pharmaceuticals, ensuring equal treatment for all shareholders. This ESOP exercise demonstrates the company's commitment to employee participation in its growth and value creation.